Patents by Inventor Michael Xia

Michael Xia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline forms of a FGFR inhibitor and processes for preparing the same
    Patent number: 11472801
    Abstract: The present disclosure relates to solid forms of N-{[2?-(2,6-difluoro-3,5-dimethoxyphenyl)-3?-oxo-2?,3?-dihydro-1?H-spiro[cyclopropane-1,4?-[2,7]naphthyridin]-6?-yl]methyl}acrylamide, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: October 18, 2022
    Assignee: Incyte Corporation
    Inventors: Yongchun Pan, Chongsheng Eric Shi, Ming Tao, Wayne Han, Michael Xia, Dengjin Wang, Zhongjiang Jia, Jiacheng Zhou, Qun Li
  • PROCESS OF PREPARING A PD-1/PD-L1 INHIBITOR
    Publication number: 20220144830
    Abstract: The present invention relates to processes of preparing PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2?-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, or salts thereof, related synthetic intermediates, and salts of the intermediates, where the PD-1/PD-L1 inhibitor is useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Application
    Filed: November 5, 2021
    Publication date: May 12, 2022
    Inventors: Jiacheng Zhou, Shili Chen, Zhongjiang Jia, Yi Li, Qiyan Lin, Pingli Liu, Yongchun Pan, Timothy Martin, Bo Shen, Chongsheng Eric Shi, Naijing Su, Yongzhong Wu, Michael Xia
  • PROCESS AND INTERMEDIATES FOR PREPARING A JAK1 INHIBITOR
    Publication number: 20220056034
    Abstract: The present invention is related to processes for preparing itacitinib, or a salt thereof, and related synthetic intermediates related thereto.
    Type: Application
    Filed: August 17, 2021
    Publication date: February 24, 2022
    Inventors: Jiacheng Zhou, Shili Chen, Pingli Liu, David J. Meloni, Yongchun Pan, Naijing Su, Michael Xia
  • PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR
    Publication number: 20220056035
    Abstract: The present invention is related to processes for preparing ruxolitinib, or a salt thereof, and related synthetic intermediates related thereto.
    Type: Application
    Filed: August 17, 2021
    Publication date: February 24, 2022
    Inventors: Jiacheng Zhou, Shili Chen, Pingli Liu, David J. Meloni, James M. Parks, Yongchun Pan, Naijing Su, Michael Xia
  • SALTS AND PROCESSES OF PREPARING A PI3K INHIBITOR
    Publication number: 20220024934
    Abstract: The present application provides processes for preparing (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, which is useful as an inhibitor phosphoinositide 3-kinase-delta (PI3K?), as well as a salt form and intermediates related thereto.
    Type: Application
    Filed: July 1, 2021
    Publication date: January 27, 2022
    Inventors: Lei Qiao, Lingkai Weng, Chongsheng Eric Shi, David Meloni, Qiyan Lin, Michael Xia, Vaqar Sharief, William Frietze, Zhongjiang Jia, Yongchun Pan, Pingli Liu, Tai-Yuen Yue, Jiacheng Zhou
  • Processes for Preparing Jak Inhibitors and Related Intermediate Compounds
    Publication number: 20210253584
    Abstract: The present invention is related to processes for preparing chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines of Formula III, and related synthetic intermediate compounds. The chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines are useful as inhibitors of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases.
    Type: Application
    Filed: February 16, 2021
    Publication date: August 19, 2021
    Inventors: Jiacheng Zhou, Pingli Liu, Qiyan Lin, Brian W. Metcalf, David Meloni, Yongchun Pan, Michael Xia, Mei Li, Tai-Yuen Yue, James D. Rodgers, Haisheng Wang
  • SALTS OF A PIM KINASE INHIBITOR
    Publication number: 20210155605
    Abstract: The present invention relates to salt forms of the Pim kinase inhibitor N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of Pim kinase-related diseases such as cancer.
    Type: Application
    Filed: January 13, 2021
    Publication date: May 27, 2021
    Inventors: Zhongjiang Jia, Ganfeng Cao, Qiyan Lin, Yongchun Pan, Lei Qiao, Vaqar Sharief, Chongsheng Eric Shi, Michael Xia, Changsheng Zheng, Jiacheng Zhou, Qun Li
  • CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME
    Publication number: 20200270245
    Abstract: The present disclosure relates to solid forms of N-{[2?-(2,6-difluoro-3,5-dimethoxyphenyl)-3?-oxo-2?,3?-dihydro-1?H-spiro[cyclopropane-1,4?-[2,7]naphthyridin]-6?-yl]methyl}acrylamide, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer.
    Type: Application
    Filed: February 6, 2020
    Publication date: August 27, 2020
    Inventors: Yongchun Pan, Chongsheng Eric Shi, Ming Tao, Wayne Han, Michael Xia, Dengjin Wang, Zhongjiang Jia, Jiacheng Zhou, Qun Li
  • CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME
    Publication number: 20190055237
    Abstract: The present disclosure relates to solid forms of N-{[2?-(2,6-difluoro-3,5-dimethoxyphenyl)-3?-oxo-2?,3?-dihydro-1?H-spiro[cyclopropane-1,4?-[2,7]naphthyridin]-6?-yl]methyl}acrylamide, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer.
    Type: Application
    Filed: May 25, 2018
    Publication date: February 21, 2019
    Inventors: Yongchun Pan, Chongsheng Eric Shi, Ming Tao, Wayne Han, Michael Xia, Dengjin Wang, Zhongjiang Jia, Jiacheng Zhou, Qun Li
  • PROCESSES OF PREPARING A JAK1 INHIBITOR AND NEW FORMS THERETO
    Publication number: 20180099978
    Abstract: This invention relates to processes for preparing a JAK1 inhibitor having Formula Ia: as well as new forms of the inhibitor.
    Type: Application
    Filed: September 22, 2017
    Publication date: April 12, 2018
    Inventors: Jiacheng Zhou, Pingli Liu, Shili Chen, Yongzhong Wu, Dengjin Wang, Zhongjiang Jia, Lei Qiao, William Frietze, Michael Xia, Yingrui Dai
  • Processes for preparing pyrazolyl-substituted pyrrolo[2,3-d]pyrimidines
    Patent number: 9908888
    Abstract: The present invention is related to processes for preparing chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines of Formula III, and related synthetic intermediate compounds. The chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines are useful as inhibitors of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: March 6, 2018
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Jiacheng Zhou, Pingli Liu, Qiyan Lin, Brian W. Metcalf, David Meloni, Yongchun Pan, Michael Xia, Mei Li, Tai-Yuen Yue, James D. Rodgers, Haisheng Wang
  • Processes and intermediates for making a JAK inhibitor
    Patent number: 9714233
    Abstract: This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of Janus kinases (JAK) including inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: July 25, 2017
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Pingli Liu, Dengjin Wang, Yongzhong Wu, Ganfeng Cao, Michael Xia
  • SALTS OF A PIM KINASE INHIBITOR
    Publication number: 20170121310
    Abstract: The present invention relates to salt forms of the Pim kinase inhibitor N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of Pim kinase-related diseases such as cancer.
    Type: Application
    Filed: September 9, 2016
    Publication date: May 4, 2017
    Inventors: Zhongjiang Jia, Ganfeng Cao, Qiyan Lin, Yongchun Pan, Lei Qiao, Vaqar Sharief, Chongsheng Eric Shi, Michael Xia, Changsheng Zheng, Jiacheng Zhou, Qun Li
  • PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR
    Publication number: 20160347734
    Abstract: This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of Janus kinases (JAK) including inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Application
    Filed: December 21, 2015
    Publication date: December 1, 2016
    Applicants: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Pingli Liu, Dengjin Wang, Yongzhong Wu, Ganfeng Cao, Michael Xia
  • SALTS AND PROCESSES OF PREPARING A PI3K INHIBITOR
    Publication number: 20160257689
    Abstract: The present application provides processes for preparing (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, which is useful as an inhibitor phosphoinositide 3-kinase-delta (PI3K?), as well as a salt form and intermediates related thereto.
    Type: Application
    Filed: February 26, 2016
    Publication date: September 8, 2016
    Inventors: Lei Qiao, Lingkai Weng, ChongShen Eric Shi, David Meloni, Qiyan Lin, Michael Xia, Vaqar Sharief, William Frietze, Zhongjiang Jia, Yongchun Pan, Pingli Liu, Tai-Yuen Yue, Jiacheng Zhou
  • PROCESSES OF PREPARING A JAK1 INHIBITOR AND NEW FORMS THERETO
    Publication number: 20150344497
    Abstract: This invention relates to processes for preparing a JAK1 inhibitor having Formula Ia: as well as new forms of the inhibitor.
    Type: Application
    Filed: April 29, 2015
    Publication date: December 3, 2015
    Applicant: INCYTE CORPORATION
    Inventors: Jiacheng Zhou, Pingli Liu, Shili Chen, Yongzhong Wu, Dengjin Wang, Zhongjiang Jia, Lei Qiao, William Frietze, Michael Xia, Yingrui Dai
  • PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR
    Publication number: 20150183805
    Abstract: This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of Janus kinases (JAK) including inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Application
    Filed: March 11, 2015
    Publication date: July 2, 2015
    Inventors: Pingli Liu, Dengjin Wang, Yongzhong Wu, Ganfeng Cao, Michael Xia
  • Processes for preparing JAK inhibitors and related intermediate compounds
    Patent number: 9000161
    Abstract: The present invention is related to processes for preparing chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines of Formula III, and related synthetic intermediate compounds. The chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines are useful as inhibitors of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: April 7, 2015
    Assignee: Incyte Corporation
    Inventors: Jiacheng Zhou, Pingli Liu, Qiyan Lin, David Meloni, Yongchun Pan, Michael Xia, Mei Li, Tai-Yuen Yue, Brian W. Metcalf
  • Processes and intermediates for making a JAK inhibitor
    Patent number: 8987443
    Abstract: This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of Janus kinases (JAK) including inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: March 24, 2015
    Assignee: Incyte Corporation
    Inventors: Pingli Liu, Dengjin Wang, Yongzhong Wu, Ganfeng Cao, Michael Xia
  • PURINONE DERIVATIVES AS HM74A AGONISTS
    Publication number: 20140371216
    Abstract: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.
    Type: Application
    Filed: April 18, 2014
    Publication date: December 18, 2014
    Applicant: Incyte Corporation
    Inventors: Changsheng Zheng, Chu-Biao Xue, Ganfeng Cao, Michael Xia, Anlai Wang, Hai Fen Ye, Brian Metcalf